DLA Piper advised Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company, in its US$50 million initial public offering. The company is focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology.
The DLA Piper team representing Liquidia was led by partner Andrew Gilbert (Short Hills) and included partners Cathryn Le Regulski (Northern Virginia), Rebecca Jones Mc Knight (Austin), Rita Patel (Washington, DC); and associates Michael Goldstein and Brian Tribuna (both of Short Hills), and Brittany McCants (Washington, DC).
DLA Piper's global life sciences lawyers work across practice areas and offices to support biotechnology and medical device clients at every stage of growth, from startups to fast-growing and mid-market businesses to mature global enterprises. According to Mergermarket's league tables for legal advisors, DLA Piper again earned the No. 1 ranking globally in 2017 for overall deal volume.